Your research abstract title should clearly indicate the main focus and reflect the scope of your research. Include key terms, keep it concise, and avoid jargon. Remember, characters in your title are included in the size limit.

Author information does not count towards the character limit.

The Submitting Author is automatically listed as first and presenting author. You may change this after adding additional authors. It is the submitting author’s responsibility to notify all named authors that they will be listed as co-authors on the abstract.

The Presenting Author will be the only one to receive the acceptance or rejection notification on 20 December. It is their responsibility to inform all co-authors of the submission’s outcome. If the abstract is accepted, a presentation invitation will be sent to the Presenting Author on 10 January, 2025. They will have until 31 January to confirm or withdraw the presentation, or to change the presenting author to another co-author listed on the abstract. The Presenting Author must register for and attend the Annual Meeting in person.

Co-Authors included should be those who contribute significantly to the intellectual content of the abstract (maximum 50 authors). When adding authors, include the Full Name, Degree, Affiliation, and Email Address of each author. You can use the ISHLT database search tool on the submission site to find and add your authors. Authors will be listed in the author block in the order they are added but can be rearranged after adding.

Your abstract can be submitted only once. Submitting the same abstract to different categories or splitting one study into multiple abstracts is not allowed. If the abstracts are too similar to be considered separate studies or if the same abstract is submitted to multiple categories, all versions may be rejected.

Research Abstract Categories are separated into four core therapies:

• HEART (Advanced Heart Failure & Transplantation)
• LUNG (Advanced Lung Failure & Transplantation)
• MCS (Mechanical Circulatory Support)
• PVD (Pulmonary Vascular Disease (PAH & CTEPH)

You will select only one of the following categories:

HEART

• HEART-Basic Science-Immunology, Inflammation, Biomarkers
• HEART-Basic Science-Models of Organ Preservation, Perfusion, Regeneration, and Graft Injury
• HEART-Basic Science-Translational Research/Genetics/Multiomics
• HEART-Basic Science-Xenotransplantation/Artificial Organs/Cell Therapy
• HEART-Cardiac Allograft Vasculopathy
• HEART-Clinical Ex-Vivo Perfusion and Preservation/Normothermic Regional Perfusion
• HEART-Critical Care Medicine/Peri-operative/Intra-operative Management
• HEART-Donor Management (including DCD and DBD)
• HEART-Health Equity, Economics, Ethics, Public Policy
• HEART-Healthcare Delivery and Quality Improvement
• HEART-Immunology, Inflammation (Clinical)
• HEART-Infectious Diseases-Diagnostics, Management, Therapeutics
• HEART-Multi-Organ Transplant
• HEART-Nursing/Allied Health/Other
• HEART-Organ Allocation, Policy, and Utilization
• HEART-Other (Clinical)
• HEART-Outcomes (Effectiveness)
• HEART-Outcomes (Other)
• HEART-Outcomes (Safety, Risk Prediction/Modelling)
• HEART-Pathology, Diagnostics, and Imaging
• HEART-Patient Centered Outcomes, Psychosocial, Quality of Life, Palliative Care
• HEART-Pediatric Heart Failure and Congenital Heart Disease Management
• HEART-Pediatric Other
• HEART-Pediatric Outcomes
• HEART-Pediatric Patient Selection, Organ Allocation, Donor Management
• HEART-Pharmacology, Therapeutics, Immunosuppression
• HEART-Primary Graft Dysfunction
• HEART-Rejection-ACR or AMR

LUNG

• LUNG-Artificial Intelligence in Lung Transplantation
• LUNG-Basic Science-Artificial Lungs
• LUNG-Basic Science-Ex-Vivo Perfusion
• LUNG-Basic Science-Immunology, Inflammation, Biomarkers (Animal/Experimental)
• LUNG-Basic Science-Immunology, Inflammation, Biomarkers (Human/Observational)
• LUNG-Basic Science-Models of Organ Preservation and Graft Injury
• LUNG-Basic Science-Translational Research/Genetics/Multiomics
• LUNG-Chronic Lung Allograft Dysfunction (Management/Therapies)
• LUNG-Chronic Lung Allograft Dysfunction (Monitoring/Diagnosis)
• LUNG-Clinical Ex-Vivo Perfusion
• LUNG-Clinical Immunology, Inflammation
• LUNG-Clinical Immunosuppression and Desensitization Strategies
• LUNG-Clinical Organ Preservation
• LUNG-Donor Management and Organ Allocation
• LUNG-Extra Corporeal Life Support (ECLS)
• LUNG-Health Equity, Economics, Ethics, Public Policy
• LUNG-Infectious Diseases (Diagnostics and Complications)
• LUNG-Infectious Diseases (Management and Therapeutics)
• LUNG-Multidisciplinary Team Care Delivery (Protocols, Quality Improvement, Service Development)
• LUNG-Nursing/Allied Health/Other
• LUNG-Pathology and Clinical Diagnostics
• LUNG-Patient Centered Outcomes, Psychosocial, Quality of Life, Palliative Care
• LUNG-Pediatrics
• LUNG-Perioperative Management
• LUNG-Primary Graft Dysfunction
• LUNG-Recipient Selection for Transplant and/or Advanced Therapies
• LUNG-Rejection (Antibody Mediated Rejection)
• LUNG-Rejection (Cellular and ALAD)
• LUNG-Surgical Aspects of Lung Transplantation
• LUNG-Survival/Prognostication/Risk-Stratification

MCS

• MCS-Basic Science-Translational Research/Genetics/Multiomics
• MCS-Cardiogenic Shock (Biventricular/Right Temporary Circulatory Support)
• MCS-Cardiogenic Shock (Left Temporary Circulatory Support)
• MCS-Cardiogenic Shock (Outcomes Research/Clinical Trials/Patient Management)
• MCS-Durable-Arrhythmias, ICDs and Right Heart Failure
• MCS-Health Equity, Economics, Ethics, Public Policy
• MCS-Hemocompatibility/Stroke/Anticoagulation/GI Bleeding
• MCS-Infectious Complications
• MCS-Long-term Outcomes-Durable MCS
• MCS-Myocardial Recovery/Pharmacotherapy
• MCS-Novel Temporary and Durable Devices/Engineering
• MCS-Nursing/Allied Health/Other
• MCS-Patient Centered Outcomes, Psychosocial, Quality of Life, Palliative Care
• MCS-Pediatrics/Congenital Heart Disease
• MCS-Selection, Pre and Post-operative Optimization in Durable MCS
• MCS-Surgical Techniques/Perioperative Management Durable MCS
  

PVD

• PVD-Artificial Intelligence/Innovations in Pulmonary Hypertension
• PVD-Basic Science/Translational Research/Genetics/Multiomics
• PVD-Health Equity, Economics, Ethics, Public Policy
• PVD-Nursing/Allied Health/Other
• PVD-Other
• PVD-Patient Centered Outcomes, Psychosocial, Quality of Life, Palliative Care
• PVD-Pediatric Pulmonary Hypertension
• PVD-RV Physiology and Imaging including Right Heart Failure (acute or chronic)
• PVD-Surgical/Interventional/Perioperative Considerations
• PVD-WHO Group I Pulmonary Arterial Hypertension
• PVD-WHO Group II PH Left Heart Disease
• PVD-WHO Group III PH Lung Disease
• PVD-WHO Group IV CTEPH (including CTED)

You will be asked to select the Primary Practice Area most relevant to your research abstract (which might not be your primary practice area), the Secondary Practice Area, and any additional practice areas applicable from the following list:

• Anesthesiology and Critical Care
• Cardiology
• Cardiothoracic Surgery
• Infectious Diseases
• Nursing and Allied Health
• Pathology
• Pediatrics
• Pharmacy
• Pulmonology
• Research and Immunology

Each year, the ISHLT offers eligible Presenting Authors of research abstracts the opportunity to be considered for the Philip K. Caves Award and the Early Career Scientist Award. You will answer questions on the submission site to determine the Presenting Author’s eigibility for these awards. For more information about these awards, visit Scientific Abstract Awards.

Note: “Early Career” is defined as an individual whose formal professional training was completed six or less years ago.

Several questions will be asked regarding funding:

• Is the presenting author an employee or owner of a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients? (Yes/No). If yes, identify the healthcare company.
• Is this abstract being funded (in part or in whole) by a healthcare company? (Yes/No). If yes, identify the healthcare company.
• Does this abstract involve data from an ISHLT Registry? (Yes/No). If Yes, identify the Registry: ISHLT Thoracic Transplant Registry or IMACS Registry
• Is this abstract based on work that was funded entirely or in part by an ISHLT grant/award? (Yes/No). If Yes, identify the grant/award.

In this step, the body of the abstract (Purpose, Methods, Results, and Conclusion) and any tables or images are entered. Follow the links on the site to enter each element. Remember, a table or image removes 320 characters from the limit.

• Purpose: Provides the rationale and objectives of the study. It explains why the research was conducted and what specific question or problem the study aims to address.
• Methods: Describes the research design, procedures, and analytical techniques used to conduct the study, including details about the sample population, experimental setup, data collection methods, and statistical analyses.
• Results: Presents the key findings of the study, including data and statistics that support the outcomes such as numerical results, tables, or figures. The results should be concise and focus on the most important findings without interpreting them.
• Conclusion: Interprets the results and explains their implications. It summarizes the main findings and their significance, discusses the study’s limitations, and suggests potential future research directions.

A $25 (USD) processing fee must accompany each abstract. ISHLT accepts payment only in the form of MasterCard, Visa and American Express. Purchase orders, checks, and electronic bank transfers will not be accepted. This fee is non-refundable and used to cover the cost of submission and processing.

Use this opportunity to proofread your submission carefully. You can make corrections to any portion, including authors, up until the deadline. Edits to a submission are not permitted after the deadline.

If all submission steps are completed, the page will indicate the submission is COMPLETE and no further action is required. If one or more submission steps are not completed, the page will indicate the submission is INCOMPLETE and ask you to complete the required steps before the submission can be marked COMPLETE.